ATE257010T1 - Nichtkristalline feste dispergierende zusammensetzung mit cefuroximaxetil - Google Patents

Nichtkristalline feste dispergierende zusammensetzung mit cefuroximaxetil

Info

Publication number
ATE257010T1
ATE257010T1 AT99117885T AT99117885T ATE257010T1 AT E257010 T1 ATE257010 T1 AT E257010T1 AT 99117885 T AT99117885 T AT 99117885T AT 99117885 T AT99117885 T AT 99117885T AT E257010 T1 ATE257010 T1 AT E257010T1
Authority
AT
Austria
Prior art keywords
cefuroximaxetil
cefuroxime axetil
composition containing
crystalline solid
organic solvent
Prior art date
Application number
AT99117885T
Other languages
English (en)
Inventor
Jong-Soo Woo
Cheoncheon-Dong
Hee-Chul Chang
Hwajeong-Dong
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE257010T1 publication Critical patent/ATE257010T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT99117885T 1999-08-04 1999-09-10 Nichtkristalline feste dispergierende zusammensetzung mit cefuroximaxetil ATE257010T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990031989A KR100342943B1 (ko) 1999-08-04 1999-08-04 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Publications (1)

Publication Number Publication Date
ATE257010T1 true ATE257010T1 (de) 2004-01-15

Family

ID=19606197

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99117885T ATE257010T1 (de) 1999-08-04 1999-09-10 Nichtkristalline feste dispergierende zusammensetzung mit cefuroximaxetil

Country Status (19)

Country Link
US (1) US6107290A (de)
EP (1) EP1080721B1 (de)
JP (1) JP3479244B2 (de)
KR (1) KR100342943B1 (de)
CN (1) CN1189161C (de)
AT (1) ATE257010T1 (de)
AU (1) AU769451B2 (de)
CA (1) CA2378267A1 (de)
CZ (1) CZ2002372A3 (de)
DE (1) DE69913958T2 (de)
ES (1) ES2212438T3 (de)
HU (1) HUP0202192A3 (de)
MX (1) MXPA02001116A (de)
NZ (1) NZ516760A (de)
RU (1) RU2215521C1 (de)
SI (1) SI20747A (de)
TR (1) TR200200287T2 (de)
WO (1) WO2001010410A1 (de)
YU (1) YU7502A (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
IN191496B (de) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
KR100362230B1 (ko) * 2000-04-21 2002-11-23 주식회사 대웅제약 저융점 무정형 세푸록심 악세틸의 제조방법
WO2002043707A1 (en) * 2000-12-01 2002-06-06 Abdul Rehman Khan Pharmaceutical formulation
US6779246B2 (en) * 2001-04-23 2004-08-24 Appleton Papers Inc. Method and system for forming RF reflective pathways
US6892441B2 (en) * 2001-04-23 2005-05-17 Appleton Papers Inc. Method for forming electrically conductive pathways
OA12625A (en) * 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
EP1469832B2 (de) 2002-02-01 2016-10-26 Bend Research, Inc. Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
TW200403075A (en) * 2002-05-29 2004-03-01 Akzo Nobel Nv Progestagenic dosage units
KR100523082B1 (ko) * 2002-09-11 2005-10-20 (주)다산메디켐 쓴 맛이 은폐된 세푸록심악세틸 제제의 제약조성물 및 그의 제조방법
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
CA2532931A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
ES2379631T3 (es) * 2003-10-08 2012-04-30 Meiji Seika Pharma Co., Ltd. Composición antibacteriana no cristalina que contiene cefditoren pivoxilo
JP2007517864A (ja) * 2004-01-09 2007-07-05 ハンミ ファーム． シーオー．， エルティーディー． セフロキシムアキセチル顆粒及びこの製造方法
KR100801589B1 (ko) 2004-01-09 2008-02-05 한미약품 주식회사 세푸록심 악세틸 과립 및 이의 제조방법
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
JP5893461B2 (ja) 2011-04-07 2016-03-23 日産自動車株式会社 位置検出装置および位置検出方法
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물
TWI586379B (zh) 2015-06-29 2017-06-11 永信藥品工業股份有限公司 一種製作難溶藥物固體劑型的方法
CN116284050B (zh) * 2022-12-19 2024-04-12 华北制药河北华民药业有限责任公司 一种高效率结晶型头孢呋辛酯转无定型粉体的方法及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
IN186539B (de) * 1997-09-29 2001-09-29 Ranbaxy Lab Ltd
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Also Published As

Publication number Publication date
DE69913958T2 (de) 2004-06-09
YU7502A (sh) 2004-09-03
US6107290A (en) 2000-08-22
HUP0202192A2 (en) 2002-10-28
CN1367683A (zh) 2002-09-04
CA2378267A1 (en) 2001-02-15
KR20010016826A (ko) 2001-03-05
EP1080721A3 (de) 2001-05-02
HUP0202192A3 (en) 2004-04-28
TR200200287T2 (tr) 2002-07-22
EP1080721A2 (de) 2001-03-07
RU2215521C1 (ru) 2003-11-10
DE69913958D1 (de) 2004-02-05
JP2001048777A (ja) 2001-02-20
AU5855100A (en) 2001-03-05
WO2001010410A1 (en) 2001-02-15
CN1189161C (zh) 2005-02-16
KR100342943B1 (ko) 2002-07-02
NZ516760A (en) 2004-01-30
SI20747A (sl) 2002-06-30
ES2212438T3 (es) 2004-07-16
AU769451B2 (en) 2004-01-29
EP1080721B1 (de) 2004-01-02
MXPA02001116A (es) 2002-08-20
CZ2002372A3 (cs) 2002-06-12
JP3479244B2 (ja) 2003-12-15

Similar Documents

Publication Publication Date Title
ATE257010T1 (de) Nichtkristalline feste dispergierende zusammensetzung mit cefuroximaxetil
EA200200119A1 (ru) β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ
CO5280070A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
CA2053253A1 (en) New aryl-and heteroarylethenylene derivatives and process for their preparation
NO953146D0 (no) Biologisk aktive 3-substituerte oksindolderivater som er nyttige som antiangiogeniske midler
NO982606D0 (no) Naftylsubstituerte benzimidazolderivater som antikoagulanter
RU2002112227A (ru) Производные пятичленных гетероциклов, способ их получения и их применение в качестве лекарственных средств
TR200102959T2 (tr) İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
ATE138921T1 (de) Xanthinderivate
RU2002105504A (ru) Твердый диспергирующий агент некристаллического цефуроксим-аксетила, способ его получения и композиция для его перорального введения
CA2168097A1 (en) Substituted 2-aminotetralins
EA200000023A1 (ru) Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
ZA993081B (en) Novel aqueous process for manufacturing paroxetine solid dispersions.
DE69431069T2 (de) Cyclische amidderivate als neurokinin a antagonisten
NO324229B1 (no) 2-hydroksymutilinkarbamat-derivater, anvendelse derav, farmasoytisk sammensetning samt fremgangsmate for fremstilling av en slik forbindelse
YU4795A (sh) Derivati indola koji se mogu koristiti kao 5ht agonisti, farmaceutski preparati koji ih sadrže i postupci njihovog dobijanja
AR029499A1 (es) Derivados de pirrolidina, farmaceuticamente activos, aplicables en el tratamiento y/o prevencion de partos y/o nacimientos prematuros y/o dismenorrea, uso de dichos derivados en la preparacion de composiciones farmaceuticas para dichos tratamientos y proceso de preparacion de los derivados mencionad
PT102145B (pt) Composicoes farmaceuticas a base de derivados de piperazina acetamida
LV10949A (lv) Aizvietoti 4-fenil-4piperidinkarboksamidi to iegusanas panemiens farmaceitiska kompozicija
ATE239722T1 (de) Benzofurylpiperazine als serotonin-agonisten
TR199700828T1 (xx) .Klavulanik asit tuzlar�.
SE9101483L (sv) Foerfarande foer upploesning av 3-(4-substituerad- fenyl)-glycidinsyraderivat
EP1241165A4 (de) Optisch aktive chroman- und thiochromanderivate
KR840005140A (ko) 인돌리진 유도체의 제조방법

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties